Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

GARD is a pan-cancer predictor of radiation therapy benefit

View ORCID ProfileJacob G. Scott, Geoffrey Sedor, Patrick Ellsworth, View ORCID ProfileJessica A. Scarborough, Kamran Ahmed, Daniel E. Oliver, View ORCID ProfileSteven A. Eschrich, View ORCID ProfileJavier F. Torres-Roca, View ORCID ProfileMichael W. Kattan
doi: https://doi.org/10.1101/2020.12.19.20248484
Jacob G. Scott
1Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
2Radiation Oncology Department, Cleveland Clinic, Cleveland, OH
3Systems Biology and Bioinformatics, School of Medicine, Case Western Reserve University, Cleveland, OH
4School of Medicine, Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jacob G. Scott
  • For correspondence: scottj10@ccf.org javier.torresroca@moffitt.org kattanm@ccf.org
Geoffrey Sedor
4School of Medicine, Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Ellsworth
4School of Medicine, Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica A. Scarborough
1Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Systems Biology and Bioinformatics, School of Medicine, Case Western Reserve University, Cleveland, OH
4School of Medicine, Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jessica A. Scarborough
Kamran Ahmed
5Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel E. Oliver
5Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Eschrich
6Department of Biostatistics and Biomedical Informatics, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven A. Eschrich
Javier F. Torres-Roca
5Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Javier F. Torres-Roca
  • For correspondence: scottj10@ccf.org javier.torresroca@moffitt.org kattanm@ccf.org
Michael W. Kattan
7Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael W. Kattan
  • For correspondence: scottj10@ccf.org javier.torresroca@moffitt.org kattanm@ccf.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Despite advances in cancer genomics, radiation therapy (RT) is still prescribed based on an empiric one-size-fits-all paradigm. Previously, we proposed a novel algorithm using the genomic adjusted radiation dose (GARD) to personalize RT prescription dose based on the biological effect of a given physical RT dose, calculated using individual tumor genomics. We hypothesize that GARD will reveal interpatient heterogeneity associated with opportunities to improve outcomes compared to physical RT dose alone. To test this hypothesis, and the GARD-based RT dosing paradigm, we performed a pooled pan-cancer analysis in 11 separate clinical cohorts of 1,615 unique patients with 7 different cancer types that represent all available cohorts with the data required to calculate GARD, together with clinical outcome.

Methods Using 11 previously-published datasets of cancers including breast, head and neck, non-small cell lung, pancreas, endometrium, melanoma and glioma, we defined two clinical endpoints: (i) time to first recurrence and (ii) overall survival, comprising 1,298 (982 +RT, 316 -RT) and 677 patients (424 +RT, 253 -RT), respectively. We used Cox regression stratified by cohort to test association between GARD and outcome with separate models using RT dose and sham-GARD for comparison. Interaction tests between GARD and treatment (+/- RT) were performed using the Wald statistic.

Results Pooled analysis of all available data reveal that GARD as a continuous variable is associated with recurrence (HR = 0.982, CI [0.970, 0.994], p = 0.002) and survival (HR = 0.970, CI [0.953, 0.988], p = 0.001). The interaction test revealed the effect of GARD on survival depends on whether or not that patient received RT (Wald statistic: p=0.011). Physical RT dose and sham-GARD were not significantly associated with either outcome.

Conclusions The biologic effect of radiation therapy, as quantified by GARD, is significantly associated with recurrence and survival for those patients treated with radiation: it is predictive of RT benefit; and physical RT dose is not. We propose integration of genomics into radiation dosing decisions, using a GARD-based framework, as the new paradigm for personalizing RT prescription dose.

Competing Interest Statement

JGS, SAE and JFTR hold IP on RSI, GARD and RxRSI, in addition to equity in Cvergenx, a company which seeks to commercialize these methods.

Funding Statement

No funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This is a retrospective analysis of published data, information on IRB approvals are contained in cited publications.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Peer-review revealed several statistical weaknesses, which have now been resolved.

Data Availability

All data are published previously in this pooled analysis. The code (and data) are available on github.

https://github.com/gsedor/GARD_Meta-Analysis

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 20, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
GARD is a pan-cancer predictor of radiation therapy benefit
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
GARD is a pan-cancer predictor of radiation therapy benefit
Jacob G. Scott, Geoffrey Sedor, Patrick Ellsworth, Jessica A. Scarborough, Kamran Ahmed, Daniel E. Oliver, Steven A. Eschrich, Javier F. Torres-Roca, Michael W. Kattan
medRxiv 2020.12.19.20248484; doi: https://doi.org/10.1101/2020.12.19.20248484
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
GARD is a pan-cancer predictor of radiation therapy benefit
Jacob G. Scott, Geoffrey Sedor, Patrick Ellsworth, Jessica A. Scarborough, Kamran Ahmed, Daniel E. Oliver, Steven A. Eschrich, Javier F. Torres-Roca, Michael W. Kattan
medRxiv 2020.12.19.20248484; doi: https://doi.org/10.1101/2020.12.19.20248484

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1244)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (532)
  • Epidemiology (10027)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2462)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1645)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (250)
  • HIV/AIDS (535)
  • Infectious Diseases (except HIV/AIDS) (11871)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2289)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1248)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (733)
  • Pharmacology and Therapeutics (314)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4840)
  • Radiology and Imaging (838)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (286)
  • Sexual and Reproductive Health (240)
  • Sports Medicine (227)
  • Surgery (268)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)